Skip to main content
. 2014 Oct;10(7):1529–1538. doi: 10.1016/j.nano.2013.12.011

Figure 5.

Figure 5

Comparative iron absorption and bioavailability of ligand-modified ferrihydrite. (A) Effect of ferrozine on the absorption of soluble ferric iron (i.e. Fe(III) NTA) and nanoparticulate, tartrate-modified ferrihydrite (i.e. LM-Fh) in male CD1 mice. Mice were orally gavaged with 59Fe-labeled compounds with (open bars) or without (closed bars) ferrozine treatment as detailed in Methods. Values are mean ± SD, n = 7 per group. ***P = 0.0009; ****P < 0.0001; other comparisons are not significantly different. (B) Hemoglobin levels of anemic Sprague–Dawley male rats following 2-week treatment with diets fortified with the different iron compounds: No Fe = control diet with no supplemental iron (3.1 ± 0.6 mg Fe/kgdiet); Fh = synthetic ferrihydrite (35.7 ± 0.1 mg Fe/kgdiet); LM-Fh = tartrate-modified ferrihydrite (31.4 ± 0.5 mg Fe/kgdiet); FeSO4 = Fe(II) sulphate (35.8 ± 0.1 mg Fe/kgdiet). Tartrate-modified ferrihydrite was precipitated from an Fe(III) chloride solution in the presence of tartrate and adipate buffer (Fe/tartrate/adipate = 1:0.5:0.5). Means with a common letter are not statistically different from one another, and means labeled with **** are statistically different from the control diet (No Fe), P < 0.0001, n = 8 per group.